134 related articles for article (PubMed ID: 37018234)
1. A novel integrative multi-omics approach to unravel the genetic determinants of rare diseases with application in sinusoidal obstruction syndrome.
Waespe N; Mlakar SJ; Dupanloup I; Rezgui MA; Bittencourt H; Krajinovic M; Kuehni CE; Nava T; Ansari M
PLoS One; 2023; 18(4):e0281892. PubMed ID: 37018234
[TBL] [Abstract][Full Text] [Related]
2. Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation.
Ansari M; Petrykey K; Rezgui MA; Del Vecchio V; Cortyl J; Ralph RO; Nava T; Beaulieu P; St-Onge P; Jurkovic Mlakar S; Huezo-Diaz Curtis P; Uppugunduri CRS; Lesne L; Théoret Y; Chalandon Y; Bartelink IH; Boelens JJ; Bredius RGM; Dalle JH; Lewis V; Kangarloo BS; Peters C; Sinnett D; Bittencourt H; Krajinovic M;
Biol Blood Marrow Transplant; 2020 May; 26(5):920-927. PubMed ID: 31790828
[TBL] [Abstract][Full Text] [Related]
3. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
4. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group.
Faraci M; Bertaina A; Luksch R; Calore E; Lanino E; Saglio F; Prete A; Menconi M; De Simone G; Tintori V; Cesaro S; Santarone S; Orofino MG; Locatelli F; Zecca M
Biol Blood Marrow Transplant; 2019 Feb; 25(2):313-320. PubMed ID: 30266674
[TBL] [Abstract][Full Text] [Related]
5. Burden of illness associated with sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation.
Cao Z; Villa KF; Lipkin CB; Robinson SB; Nejadnik B; Dvorak CC
J Med Econ; 2017 Aug; 20(8):871-883. PubMed ID: 28562132
[TBL] [Abstract][Full Text] [Related]
6. Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation.
Seifert C; Wittig S; Arndt C; Gruhn B
J Cancer Res Clin Oncol; 2015 May; 141(5):877-85. PubMed ID: 25335953
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.
Pai RK; van Besien K; Hart J; Artz AS; O'Donnell PH
Leuk Lymphoma; 2012 Aug; 53(8):1552-7. PubMed ID: 22280517
[TBL] [Abstract][Full Text] [Related]
8. Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study.
Colecchia A; Ravaioli F; Sessa M; Alemanni VL; Dajti E; Marasco G; Vestito A; Zagari RM; Barbato F; Arpinati M; Cavo M; Festi D; Bonifazi F
Biol Blood Marrow Transplant; 2019 May; 25(5):995-1003. PubMed ID: 30660772
[TBL] [Abstract][Full Text] [Related]
9. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
Roeker LE; Kim HT; Glotzbecker B; Nageshwar P; Nikiforow S; Koreth J; Armand P; Cutler C; Alyea EP; Antin JH; Richardson PG; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2019 Jan; 25(1):137-144. PubMed ID: 30081073
[TBL] [Abstract][Full Text] [Related]
10. Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
El-Serafi I; Remberger M; Ringdèn O; Törlén J; Sundin M; Björklund A; Winiarski J; Mattsson J
Clin Transl Sci; 2020 Mar; 13(2):293-300. PubMed ID: 31675173
[TBL] [Abstract][Full Text] [Related]
11. Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
Abate ME; Paioli A; Cammelli S; Cesari M; Longhi A; Palmerini E; Ferrari S; Carretta E; Picci P; Piscaglia F
Bone Marrow Transplant; 2018 May; 53(5):591-599. PubMed ID: 29335623
[TBL] [Abstract][Full Text] [Related]
12. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
[TBL] [Abstract][Full Text] [Related]
13. Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
Gómez-Centurión I; Bailén R; Oarbeascoa G; Muñoz C; Luque AÁ; Boyra ME; Calleja E; Rincón D; Dorado N; Barzallo P; Anguita J; Díez-Martín JL; Kwon M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2089-2097. PubMed ID: 32791193
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Corbacioglu S; Jabbour EJ; Mohty M
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1271-1280. PubMed ID: 30797942
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
O'Donnell PH; Artz AS; Undevia SD; Pai RK; Del Cerro P; Horowitz S; Godley LA; Hart J; Innocenti F; Larson RA; Odenike OM; Stock W; Van Besien K
Leuk Lymphoma; 2010 Dec; 51(12):2240-9. PubMed ID: 20919852
[TBL] [Abstract][Full Text] [Related]
16. Defibrotide treatment but not prophylaxis is useful in hepatic sinusoidal obstruction syndrome in children undergoing autologous stem cell transplant following high-dose chemotherapy: A single-center experience from the Royal Marsden Hospital, UK.
Roy Moulik N; Johnson I; Van Bruggen L; Petterson T; Mycroft J; Vaidya SJ
Pediatr Blood Cancer; 2020 Nov; 67(11):e28677. PubMed ID: 32865880
[TBL] [Abstract][Full Text] [Related]
17. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
18. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
19. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537
[TBL] [Abstract][Full Text] [Related]
20. Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation.
Huezo-Diaz Curtis P; Uppugunduri CRS; Muthukumaran J; Rezgui MA; Peters C; Bader P; Duval M; Bittencourt H; Krajinovic M; Ansari M
Pharmacogenomics J; 2018 Jan; 18(1):64-69. PubMed ID: 27779248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
